Rituximab Maintenance Therapy for Autoimmune Pancreatitis
The dramatic response to steroids makes autoimmune pancreatitis (AIP) unique among pancreatic disorders. However, some cases are steroid-resistant, and relapse is common after steroid withdrawal. Mayo Clinic gastroenterologist Dr. Mark Topazian discusses a recent study which concludes that rituximab maintenance therapy can prolong remission. To learn more, visit https://mayocl.in/2Nz8cIz
▶︎
What Is Autoimmune Pancreatitis? Diagnosis, Types, Treatment & IgG4 Explained
▶︎
Rituximab: The Immune System's Best Friend Or Worst Enemy?
▶︎
Small Fiber Neuropathy
▶︎
My Rituxan Infusion - Side Effects, Infusion Room Tour and My Patient Experience
▶︎
Autoimmune Pancreatitis
▶︎
How do monoclonal antibodies work? Rituximab, infliximab, adalimumab and others
▶︎
IgG4 Related Diseases
▶︎
Risk of B-Cell Depleters Long-Term (Ocrevus, Rituximab, Kesimpta, Briumvi)
▶︎
RITUXAN TREATMENT EXPERIENCE
▶︎
Pancreas Cancer: What Patients Need to Know
▶︎
Addressing challenges in diagnosis and treatment of IgG4-related gastrointestinal disease
▶︎
TMA Empowerment Clinic (Living with Necrotizing Myopathy) with Dr. Andrew Mammen
▶︎
Ep.40 - Safety of rituximab for vasculitis, antinuclear antibody testing in lupus, and deprescribing
▶︎
Tuberculosis | Clinical Medicine
▶︎
Rituximab to Treat Systemic Features of Sjogren's
▶︎
Infusion Therapy: Tips and strategies from patients with vasculitis
▶︎
Autoimmune Pancreatitis: Symptoms, Diagnosis, and Treatment
▶︎
Understanding Pancreatitis
▶︎
Ocrevus, Rituxan & Kesimpta: How They Work and When to Use Them
▶︎